OR WAIT null SECS
March 22, 2021
The companies will work to discover and develop RNA-targeting small-molecule therapeutics for difficult-to-address indications.
March 15, 2021
Continuus Pharmaceuticals is building the first GMP facility using integrated continuous manufacturing technology for end-to-end production of small-molecule APIs and finished dosage forms.
March 08, 2021
USP is collaborating with Phlow to build a new lab that will develop test methods and standards to facilitate broader adoption of continuous manufacturing.
March 03, 2021
Without an independent approval pathway for novel excipients, true pharmaceutical innovation could be stymied.
Various strategies to improve bioavailability are being continuously evaluated, affording greater commercial prospects for the future.
March 02, 2021
FDA moves recommended timeline for API and drug manufacturers to assess impurity risks to March 31, 2021.
February 25, 2021
The company will join the network of approved manufacturers of the lipid excipients.
February 18, 2021
The deal expands Wavelength’s drug substance manufacturing footprint and its API CDMO business.
February 16, 2021
The increased services will work in conjunction with the site’s SimpliFiH Solutions first-in-human services, which includes phase-appropriate drug substance and drug product development and manufacturing.
February 15, 2021
Nanoform and Herantis have signed a biologics proof of concept agreement for formulation proof of concept projects aimed at improving nasal drug delivery to the brain.
